Provided by Tiger Trade Technology Pte. Ltd.

Verona Pharma plc

106.91
0.0000
Volume:- -
Turnover:200.07M
Market Cap:9.19B
PE:-104.23
High:106.91
Open:106.91
Low:106.91
Close:106.91
52wk High:106.93
52wk Low:31.09
Shares:85.99M
Float Shares:62.85M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0257
EPS(LYR):-2.1268
ROE:-36.36%
ROA:-6.68%
PB:33.04
PE(LYR):-50.27

Loading ...

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A

LiveWire
·
Nov 21, 2025

Edgewise Therapeutics Appoints Christopher Martin to Board of Directors

Reuters
·
Nov 20, 2025

Ligand Pharma Q3 revenue jumps; raises 2025 guidance

Reuters
·
Nov 06, 2025

Merck Reports Third-Quarter Sales of $17.3 Billion

Reuters
·
Oct 30, 2025

Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

TIPRANKS
·
Oct 08, 2025

Merck Completes Acquisition of Verona Pharma, Adding COPD Drug Ohtuvayre to Portfolio

Reuters
·
Oct 07, 2025

Verona Pharma shareholders approve proposed acquisition by Merck

TIPRANKS
·
Sep 25, 2025

Verona Pharma plc Held General and Court Meetings on Proposed Transaction

Reuters
·
Sep 25, 2025

Press Release: Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Dow Jones
·
Sep 25, 2025

Verona Pharma Extends Severance Benefits and Redefines Resignation Terms in New Employee Compensation Plan Amendment

Reuters
·
Sep 10, 2025

Market Chatter: Merck Selling Bonds to Help Fund Verona Acquisition

MT Newswires Live
·
Sep 02, 2025

Verona Pharma plc Announces Date for General Meeting

Reuters
·
Aug 18, 2025

Verona Pharma PLC reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 07, 2025

Director James Aloysius Brady Reports Disposal of Common Shares in Verona Pharma plc

Reuters
·
Aug 06, 2025

Director Vikas Sinha Reports Disposal of Common Shares of Verona Pharma plc

Reuters
·
Aug 06, 2025

Verona Pharma PLC expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
Aug 04, 2025

Merck & Co. Inc. Reports 2% Decrease in Q2 2025 Sales to $15.8 Billion; GAAP Net Income Drops 19%, GAAP EPS Falls 18% to $1.76

Reuters
·
Jul 29, 2025

HC Wainwright Downgrades Verona Pharma to Neutral From Buy, Adjusts Price Target to $107 From $90

MT Newswires Live
·
Jul 14, 2025

Verona Pharma Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Jul 14, 2025